Mrs. Rao, a health-conscious 55-year-old, was diagnosed with a large ovarian mass after experiencing persistent abdominal ...

The University of Pennsylvania has taken a novel approach to ensure that women with suspicious adnexal lesions are referred ...

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...

Black and American Indian patients are less likely to have elevated cancer antigen (CA)-125 levels at ovarian cancer ...

Innovent Biologics has dosed the first subject in the randomised Phase III HeriCare-Ovarian01 trial of IBI354 for treating ...

One of the most exciting developments in ovarian cancer treatment in decades will form the basis of a new two-year research ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and ...

On Monday, the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a key patent application covering Anixa Biosciences, Inc.’s (NASDAQ:ANIX) ovarian cancer vaccine ...

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation ...

Anixa Biosciences (ANIX) announced that the United States Patent and Trademark Office, USPTO, has issued a Notice of Allowance for a key patent ...

The complaint filed in a Seattle court alleges that Genmab, its subsidiary ProfoundBio that was acquired last year, and ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...